Patient-Derived Xenografts of Non Small Cell Lung Cancer: Resurgence of an Old Model for Investigation of Modern Concepts of Tailored Therapy and Cancer Stem Cells

Figure 2

Frequency of CD133⁺ cells in primary tumors is maintained in PDXs during passaging in mice independently of their initial content. Dot plots showing that the percentage of CD133⁺ cells, previously demonstrated to display stem-like features and to be spared by cisplatin treatment [REF], is similar in the primary tumor and in PDXs. CD133⁺ cells levels remain stable also after several passages in immunocompromised mice in PDX models established from low, intermediate and high CD133-expressing tumors (LT48, LT128, LT111 resp.). p = number of serial transplant in mouse. FACs analysis of CD133 expression was performed with CD133/1-phycoerythrin antibody (50 μg/mL; AC133 clone; Miltenyi Biotech).